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Abstract
Background: Non-nosocomial healthcare-associated infective endocarditis (NNHCA-IE) is a new category of IE of
increasing importance. This study described the clinical and microbiological characteristics and outcome of
NNHCA-IE in Taiwan.
Methods: A retrospective study was conducted of all patients with IE admitted to the Kaohsiung Veterans General
Hospital in Kaohsiung, Taiwan over a five-year period from July 2004 to July 2009. The clinical and microbiological
features of NNHCA-IE were compared to those of community-acquired and nosocomial IE. Predictors for in-hospital
death were determined.
Results: Two-hundred episodes of confirmed IE occurred during the study period. These included 148 (74%)
community-acquired, 30 (15%) non-nosocomial healthcare-associated, and 22 (11%) nosocomial healthcare-associated
IE. Staphylococcus aureus was the most frequent pathogen. Patients with NNHCA-IE compared to community-acquired
IE, were older (median age, 67 vs. 44, years, p < 0.001), had more MRSA (43.3% vs. 9.5%, p < 0.001), more comorbidity
conditions (median Charlson comorbidity index [interquartile range], 4[2-6] vs. 0[0-1], p < 0.001), a higher in-hospital
mortality (50.0% vs. 17.6%, p < 0.001) and were less frequently recognized by clinicians on admission (16.7% vs. 47.7%,
p = 0.002). The overall in-hospital mortality rate for all patients with IE was 25%. Shock was the strongest risk factor for
in-hospital death (odds ratio 7.8, 95% confidence interval 2.4-25.2, p < 0.001).
Conclusions: NNHCA-IE is underrecognized and carries a high mortality rate. Early recognition is crucial to provide
optimal management and improve outcome.
Background
Infective endocarditis (IE) is a serious disease with a
high mortality rate, of up to 16-25% [1-6]. Major
changes have occurred in the epidemiology of IE in
association with advances in medical and surgical care.
Rheumatic heart disease has been replaced as the major
risk factor for IE by degenerative valve diseases, hemo-
dialysis, prosthetic valve replacement, and intravenous
drug use (IVDU) [2,7-10]. Staphylococci, instead of
Streptococci, have become the most common pathogen
in IE patients in recent series [7,8,11].
Nosocomial IE is associated with the highest mortality
rate among all forms of IE [10,12]. Nosocomial acquisition
is considered when IE occurs within the hospital or in
recently hospitalized patients [12,13]. Within the past two
decades more invasive procedures and life-support mea-
sures, previously limited to hospitals are now performed in
chronic care facilities or at home. A new category of IE,
non-nosocomial healthcare-associated IE (NNHCA-IE),
was recently introduced to encompass these changes in
medical practice. This new entity is defined as an episode
of IE in out-patients who had extensive exposure to medi-
cal care [14-17].
NNHCA-IE has been reported to contribute to 9.3% of
all IE episodes [15]. The highest percentage was noted
in North America. A large prospective, multicenter,
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Endocarditis-Prospective Cohort Study (ICE-PCS) [15],
mainly focused on the Americas and Europe. Only a few
study sites were located in Western, Southern and South-
eastern Asia. A subgroup analysis for these regions has not
as yet been reported [15]. Patients with NNHCA-IE were
found to have clinical features and outcomes similar to
those with nosocomial IE [14]. Because these infections
occur outside the hospital, clinicians appear to be unaware
of the need to identify these cases and provide optimal anti-
microbial therapy.
To our knowledge, NNHCA-IE has not been reported
previously in Eastern Asia (including China, Hong Kong,
Taiwan, Japan, Mongolia, North Korea and South Korea).
Among the studies of IE conducted in this region
[4,5,18-23], only two included nosocomial IE. Nosocomial
acquisition was found to be an independent factor for
poor prognosis [4,18]. However, the definitions of nosoco-
mial IE were not clearly defined in these studies. It is also
unclear whether NNHCA-IE was adequately distinguished
from community-acquired or nosocomial-acquired IE. To
better characterize the prevalence, causative microorgan-
isms, clinical features and outcome of non-nosocomial
healthcare-associated IE in Eastern Asia, we conducted a
five-year retrospective study of all cases of IE in a large
medical center in southern Taiwan.
Methods
Patients
Medical records of patients more than 18 years old with
IE who were admitted to the Kaohsiung Veterans Gen-
eral Hospital (KVGH) from July 2004 to July 2009, were
reviewed retrospectively. KVGH is a 1,200-bed teaching
hospital. It provides both primary and tertiary medical
services in Kaohsiung, a city with 1.52 million residents
located in southern Taiwan. Medical charts of patients
who met the International Classification of Diseases,
Ninth Revision (ICD-9) diagnostic codes for endocarditis
(ICD-9 codes 421.0, 421.1, and 421.9) were reviewed by
infectious disease specialists. Diagnosis of IE were con-
firmed based on the modified Duke criteria [24]. Only
those with definite IE were included to the study. Patients
with a relapse of IE, defined as isolation of the same
pathogen within a six-month period [17], were excluded.
A standardized case report form was designed to collect
the clinical characteristics of the patients, including age,
sex, clinical manifestations, predisposing heart condi-
tions, underlying diseases, Charlson comorbidity index
[25], risk behaviors, causative microorganisms and out-
come. The study was approved by the KVGH Institu-
tional Review Board and informed consent was waived
because of the retrospective nature of the study, and lack
of direct patient contact or intervention.
Definitions
An IE episode was defined as non-nosocomial healthcare-
associated when it occurred within 48 hours of admission
in a patient fulfilling at least one of the following criteria:
(1) had received intravenous therapy, wound care, specia-
lized nursing care, hemodialysis or intravenous che-
motherapy within 30 days prior to the onset of IE, (2) was
hospitalized in an acute care hospital for 2 or more days
within 90 days before the onset of IE, or (3) resided in a
nursing home or long-term care facility before admission
[14,16,17,26]. An IE episode was defined as nosocomial
healthcare-associated if positive blood cultures were
obtained from a patient hospitalized for more than
48 hours without relevant symptoms and signs on admis-
sion [14,16,17,26,27]. The infection was considered to be
community-acquired when the symptoms and signs of IE
occurred within 48 hours of admission in a patient not
fulfilling the criteria for non-nosocomial healthcare-
associated infection. IVDU-associated IE was defined as
patients actively using illicit intravenous drugs at the time
of infection. A predisposing heart condition was defined as
a history of prosthetic cardiac valve replacement, previous
bacterial endocarditis, congenital cardiac malformation,
rheumatic and other acquired valvular dysfunction, hyper-
trophic cardiomyopathy or mitral valve prolapse with valv-
ular regurgitation [28,29]. When a patient was suspected
or diagnosed to have IE within the first 24 hours of medi-
cal access by clinicians, he was considered to be recog-
nized on admission. Appropriate antibiotics were defined
as having in vitro activities against the causative pathogens
[30].
Presenting symptoms were divided into 5 symptomatic
categories according to site: (1) constitutional including
fever, fatigue and weight loss; (2) cardiopulmonary
including dyspnea, orthopnea and chest pain; (3) neuro-
logical including change in consciousness, syncope and
focal neurological deficits; (4) gastrointestinal including
nausea, vomiting, abdominal pain and diarrhea; (5) mus-
culoskeletal including focal arthralgia or myalgia, skin
rash, subcutaneous abscess and cellulitis.
Statistical analysis
In univariate analysis, categorical variables were com-
pared using c
2 test or Fisher’s exact test as appropriate.
Continuous variables were analyzed by Mann-Whitney
U test. The result was considered to be significant if a
two-tailed p value was less than 0.05. Variables with a p
v a l u eo fl e s st h a n0 . 0 5i nu n i v a r i a t ea n a l y s i sw e r e
included in multivariate logistic regression analysis by
forward stepwise method using p values less than 0.05
as inclusion criterion and 0.1 as removal criterion. All
data were analyzed by SPSS 17.0 for Windows (SPSS
Inc. Chicago, USA).
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During the five-year study period, 481 admissions with
compatible ICD-9 codes for IE were reviewed. We identi-
fied 205 episodes of definite IE and 32 of possible IE. We
excluded 5 patients with definite IE because they were
considered to have had a relapse and all cases of possible
IE. The final study population consisted of 192 patients
with 200 episodes of definite IE, of which 168 (84%) were
diagnosed by clinical and 32 (16%) by pathological criteria.
There were 148 (74%) episodes of community-acquired
and 52 (26%) healthcare-associated IE. Thirty (57.7%) of
the 52 healthcare-associated IE were considered to be
non-nosocomial. They comprised 15% of all IE episodes.
There were 59 (29.5%) IVDU-associated IE episodes. All
of these were community-acquired. The ten patients with
IE and human immunodeficiency virus (HIV) infection
were all IVDU-associated. Paravalvular abscess was noted
in only one patient, whose IE was community-acquired.
Overall, patients who were recognized as having NNHCA-
IE more frequently received appropriate antibiotics within
the first 24 hours of presentation than those who were not
(77.6% vs. 37.6%, p < 0.001).
Of the 30 IE patients who met non-nosocomial health-
care-associated infection criteria, 14 were receiving regular
hemodialysis prior to the onset of IE, 19 were recently
hospitalized in acute care hospitals for 2 or more days
(median duration from the time being discharged to the
time IE symptoms began were 33 days, with an interquar-
tile rage of 15-55 days), 4 were nursing home residents
and 1 had received intravenous chemotherapy 7 days
before the onset of IE.
NNHCA-IE versus community-acquired IE
T h et h i r t yp a t i e n t sw i t hN N H C A - I Ew e r eo l d e r( m e d -
ian age, 67 vs. 44, years, p < 0.001), more often female
(43.3% vs. 18.9%, p = 0.006), and had more frequently
co-morbidities (median Charlson comorbidity index
[interquartile range], 4[2-6] vs. 0[0-1], p <0 . 0 0 1 )
(Table 1). Up to 60% of NNHCA-IE patients had
Charlson comorbidity indexes of 4 or more. NNHCA-
IE was more often caused by Staphylococci (76.7% vs.
50.7%, p = 0.015), methicillin-resistant Staphylococcus
aureus (MRSA) (43.3% vs. 9.5%, p < 0.001), and less
commonly by Streptococci (13.3% vs. 34.5%, p = 0.029).
Patients with NNHCA-IE had a significantly higher in-
hospital mortality rate (50.0% vs. 17.6%, p <0 . 0 0 1 ) .
NNHCA-IE versus nosocomial IE
The twenty two patients with nosocomial IE were even
older (median age, 78 vs. 67, years, p < 0.011). There
was no significant difference in gender (female, 43.3%
vs. 31.8%, p = 0.40), Charlson comorbidity index (med-
ian [interquartile range], 4[2-6] vs. 2[1-4], p =0 . 0 6 ) ,
Staphylococcal infection (76.7% vs. 77.3%, p = 1.00),
Streptococcal infection (13.3% vs. 9.1%, p = 1.00) and in-
hospital mortality rate (50.0% vs. 40.9%, p =0 . 5 2 )
between patients with NNHCA-IE and nosocomial IE.
Microbiological findings
The microbiological findings according to the site of ori-
gin are shown in Table 2. Staphylococcus aureus was the
most common causative microorganism except for non-
IVDU community-acquired IE. Streptococci remained
the most predominant causative pathogen in this group.
There were 8 culture-negative IE patients, and 3 of
them had been exposed to antimicrobial therapy before
the blood cultures were drawn for culture.
Recognition of NNHCA-IE
NNHCA-IE was less often clinically recognized on admis-
sion than community-acquired IE (5/30, 16.7% vs. 63/132,
47.7%, p = 0.002). NNHCA-IE were initially misdiagnosed
a ss k i na n ds o f tt i ssue infection (8 episodes), catheter-
related infection (5), pneumonia (4), urinary tract infection
(4), fever of undetermined focus (3) and meningitis (1).
Only 43.3% of these patients received appropriate antibio-
tics within the first 24 hours of admission. Delay of appro-
priate antimicrobial therapy was significantly associated
with in-hospital death in community-acquired IE patients
(27.8% vs. 9.9%, p = 0.007), but not in NNHCA-IE patients
(52.9% vs. 46.2%, p = 0.713).
Three significantly different clinical characteristics
w e r ei d e n t i f i e df o rN N H C A - I Ea m o n ga l lI Ee p i s o d e s
acquired outside the hospital using multivariate logistic
regression analysis, as shown in Table 3. Having a Charl-
son comorbidity index of 2 or more was the most signifi-
cant predictor (odds ratio [OR] 27.5, 95% confidence
interval [CI] 6.9-110.3, p < 0.001), followed by MRSA
infection and having a past history of hypertension.
Risk factors for in-hospital mortality
Twenty five percent of all the patients (n = 50) died during
hospitalization. Patients with NNHCA-IE had the highest
in-hospital mortality rate (15/30, 50.0%), followed by noso-
comial healthcare-associated IE (9/22, 40.9%) and commu-
nity-acquired IE (26/148, 17.6%). In-hospital mortality rate
was significantly higher in NNHCA-IE compared to com-
munity-acquired IE (p < 0.001). Risk factors significantly
associated with in-hospital death according to univariate
and multivariate analysis are shown in Table 4. In multi-
variate logistic regression analysis, the significant risk fac-
tors for in-hospital death, after adjusting for age and sex,
included shock (odds ratio 7.8, 95% confidence interval
2.4-25.2, p < 0.001), non-nosocomial healthcare-associated
infection, alteration in consciousness, delay of appropriate
antibiotics use and Staphylococci infection.
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among patients admitted to the Veterans General Hospital Kaohsiung, Taiwan over a five-year period (2004 to 2009)
All Group A:
NNHCA-IE
n=3 0
Group B:
Community-acquired IE
n = 148
Group C:
Nosocomial IE
n=2 2
Group
Av sB
p value
Group
Av sC
p value
Age, years
Median (range) 50 (19-92) 67 (45-84) 44 (19-88) 78 (43-92) < 0.001 0.011
Women, n (%) 48 (24.0) 13 (43.3) 28 (18.9) 7 (31.8) 0.004 0.399
Prosthetic valve, n (%) 18 (9.0) 2 (6.7) 15 (10.1) 1 (4.5) 0.741 1.000
Underlying diseases, n (%)
Predisposing heart
condition
49 (24.5) 6 (20.0) 40 (27.0) 3 (13.6) 0.423 0.717
Diabetes mellitus 52 (26.0) 17 (56.7) 25 (16.9) 10 (45.5) < 0.001 0.424
Hypertension 54 (27.0) 20 (66.7) 26 (17.6) 8 (36.4) < 0.001 0.030
Heart failure 35 (17.5) 4 (13.3) 25 (16.9) 6 (27.2) 0.789 0.290
HIV infected 10 (5.0) 0 (0) 10 (6.8) 0 (0) 0.216 NA
IVDU 59 (29.5) 0 (0) 59 (40.0) 0 (0) < 0.001 NA
Charlson comorbidity index,
median (IQR)
1 (0-2) 4 (2-6) 0 (0-1) 2 (1-4) < 0.001 0.06
0-1 132 (66.0) 3 (10.0) 121 (81.8) 8 (36.4)
2-3 34 (17.0) 9 (30.0) 19 (12.8) 6 (27.3)
≧4 34 (17.0) 18 (60.0) 8 (5.4) 8 (36.4)
Dental procedure 9 (4.5) 0 (0) 8 (5.4) 1 (4.5) 0.193 0.423
Symptom duration, days,
median (IQR)
1
5 (3-15) 4 (2-7) 7 (3-20) NA 0.031 NA
Symptoms, n (%)
1
Constitutional 142 (71.0) 26 (86.7) 104 (70.3) 12 (54.5) 0.065 0.010
Cardiopulmonary 65 (32.5) 6 (20.0) 50 (33.8) 9 (40.9) 0.138 0.100
Neurological 47 (23.5) 4 (13.3) 40 (27.0) 3 (13.6) 0.113 1.000
Gastrointestinal 14 (7.0) 3 (10.0) 8 (5.4) 3 (13.6) 0.399 0.689
Musculoskeletal 24 (12.0) 5 (16.7) 19 (12.8) 0 (0) 0.563 0.065
Signs, n (%)
2
Fever 165 (82.5) 28 (93.3) 121 (81.8) 16 (72.7) 0.174 0.058
Heart murmur 83 (41.5) 10 (33.3) 68 (45.9) 5 (22.7) 0.204 0.404
Skin lesions 23 (11.5) 3 (10.0) 20 (13.5) 0 (0) 0.770 0.253
Embolism 98 (49.0) 11 (36.7) 82 (55.4) 5 (22.7) 0.061 0.282
Altered consciousness 34 (17.0) 4 (13.3) 28 (18.9) 2 (9.1) 0.468 1.000
Shock 20 (10.0) 2 (6.7) 16 (10.8) 2 (9.1) 0.742 1.000
Recognition on admission,
n (%)
3
68/162 (42.0) 5/30 (16.7) 63/132 (47.7) NA 0.002 NA
Appropriate antibiotics on
admission, n (%)
4
94/165 (57.0) 13/30 (43.3) 81/135 (60.0) NA 0.095 NA
Outcome
Antibiotic treatment
duration, median days
(IQR, n)
5
32 (28-41, n = 138) 28 (27-40, n = 17) 32 (28-42, n = 113) 34 (30-40, n = 8) 0.258 0.277
Hospital stay, median days
(IQR, n)
5
37 (29-48, n = 131) 46 (30-65, n = 17) 37 (29-45, n = 114) NA 0.181 NA
In-hospital death 50 (25.0) 15 (50.0) 26 (17.6) 9 (40.9) < 0.001 0.516
1 Duration from the time of onset of symptoms to admission to hospital.
2 Includes all symptoms and signs of IE from their onset to diagnosis.
3 The number of patients who were suspected or diagnosed to have IE within the first 24 hours of medical access. Exclude patients who were referred from
other hospitals with a definite diagnosis already.
4 The number of patients who received antibiotics with in vitro activities against the pathogens within the first 24 hours of medical access.
5 Only patients who have received a complete course of antibiotics for IE were included.
NNHCA-IE, non-nosocomial healthcare-associated infective endocarditis; HIV, human immunodeficiency virus; NA, not applicable; IVDU, intravenous drug user; IQR,
interquartile range.
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Kaohsiung, Taiwan over a five-year period (2004 to 2009)
Pathogens All Community-acquired IE Healthcare-associated IE
N = 200 non-IVDU
n=8 9
IVDU
n=5 9
non-nosocomial
n=3 0
nosocomial IE
n=2 2
Staphylococci, n (%) 115 (57.5) 21 (23.6) 54 (91.5) 23 (76.7) 17 (77.3)
MSSA 65 15 42 8 0
MRSA 44 2 12 13 17
Coagulase-negative Staphylococci 64 0 2 0
Streptococci, n (%) 57 (28.5) 50 (56.2) 1 (1.7) 4 (13.3) 2 (9.1)
Viridans streptococci 38 35 0 3 0
Streptococcus bovis 98 0 1 0
Streptococcus agalactiae 53 1 0 1
Streptococcus pyogenes 11 0 0 0
Streptococcus pneumoniae 11 0 0 0
NVS 3 2 0 0 1
Enterococci, n (%) 9 (4.5) 5 (5.6) 0 (0) 3 (10.0) 1 (4.5)
Enterococcus faecalis 85 0 2 1
Enterococcus faecium 10 0 1 0
Gram negative bacilli, n (%) 3 (1.5) 0 (0) 2 (3.4) 0 (0) 1 (4.5)
Pseudomonas aeruginosa 10 1 0 0
Chryseobacterium indologenes 10 0 0 1
Enterobacter cloacae 10 1 0 0
HACEK group, n (%) 2 (1.0) 2 (2.2) 0 (0) 0 (0) 0 (0)
Haemophilus actinomycetemcomitans 11 0 0 0
Haemophilus parainfluenzae 11 0 0 0
Others, n (%) 6 (3.0) 5 (5.6) 1 (1.7) 0 (0) 0 (0)
Rothia dentocariosa 21 1 0 0
Finegoldia magna 11 0 0 0
Lactococcus lactis 11 0 0 0
Lactococcus gravieae 11 0 0 0
Candida albicans 11 0 0 0
Culture negative, n (%) 8 (4.0) 6 (6.7) 1 (1.7) 0 (0) 1 (4.5)
IE, infective endocarditis; IVDU, intravenous drug user; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus;
NVS, nutritionally variant streptococci; HACEK, Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens,
Kingella species.
Table 3 Significant differences in the clinical characteristics of patients with NNHCA-IE compared to community-
acquired IE, as determined by multivariate analysis
NNHCA-IE Community- Univariate Multivariate
1
n = 30 acquired IE
n = 148
OR (95%CI) p value OR (95%CI) p value
Age ≧ 65 years, n (%) 19 (63.3) 27 (18.2) 7.7 (3.3-18.1) < 0.001
Women, n (%) 13 (43.3) 28 (18.9) 3.3 (1.4-7.5) 0.004
Charlson comorbidity index ≧ 2 n (%) 27 (90.0) 27 (18.2) 40.3 (11.4-142.7) < 0.001 27.5 (6.9-110.3) < 0.001
Diabetes mellitus, n (%) 17 (56.7) 25 (16.9) 6.4 (2.8-14.9) < 0.001
Hypertension, n (%) 20 (66.7) 26 (17.6) 9.4 (3.9-22.4) < 0.001 7.5 (2.2-25.1) 0.001
Symptoms duration ≦ 7 days n (%) 25 (83.3) 95 (64.2) 2.8 (1.0-7.7) 0.041
Staphylococci infection, n (%) 23 (76.7) 75 (50.7) 3.2 (1.3-7.9) 0.009
MRSA infection, n (%) 13 (43.3) 14 (9.5) 7.3 (3.0-18.1) < 0.001 12.2 (2.9-51.5) 0.001
Streptococci infection, n (%) 4 (13.3) 51 (34.5) 0.3 (0.1-0.9) 0.022
1Adjusted for age and sex.
NNHCA-IE, non-nosocomial healthcare-associated infective endocarditis; OR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus.
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Non-nosocomial healthcare-associated infective endocar-
ditis (NNHCA-IE) is a new category of IE that often goes
unrecognized in Taiwan. This is the first study to describe
the clinical characteristics and outcomes of NNHCA-IE in
Eastern Asia and emphasize the differences between
NNHCA-IE and community-acquired IE. This study also
describes the changing distribution of the causative micro-
organisms of IE in Taiwan. Five independent predictors
for in-hospital death were identified.
In our study clinical features and outcomes of patients
with NNHCA-IE were very different from those with
community-acquired IE, but similar to those with noso-
comial IE. The findings were comparable to those in a
previous study[14]. However, it is easy to mistake
NNHCA-IE for community-acquired IE, since both
appear to be acquired outside the hospital. Symptoms
and signs of IE patients at presentation were not helpful
in distinguishing between these two categories of IE. We
identified 3 independent predictors for all IE episodes
acquired out of the hospital to be non-nosocomial
healthcare-associated, including having a Charlson
comorbidity index of 2 or more, having a history of
hypertension and MRSA infection. Clinicians should be
alert to the possibility of NNHCA-IE when patients with
IE present with these 3 different clinical features.
Early recognition of IE enables clinicians to initiate
appropriate antimicrobial therapy early. However, only
15.4% of NNHCA-IE patients were suspected or diagnosed
to have IE on admission. The percentage was significantly
lower than that of community-acquired IE patients. There
are two possible explanations. First, patients with
NNHCA-IE were less likely to present with embolic phe-
nomena or a heart murmur than those with community-
acquired IE. Second, many clinicians are not familiar with
the atypical presentations of the new category of IE.
Only 43.3% of patients with NNHCA-IE received
appropriate antimicrobial therapy on the first day. Delay
Table 4 Predictors for in-hospital death in 200 episodes of IE among patients admitted to the Veterans General
Hospital in Kaohsiung, Taiwan over a five-year period (2004 to 2009) as determined by multivariate analysis
Risk factors All Death Univariate Multivariate
1
OR (95%CI) p value OR (95%CI) p value
Age ≧ 65 years 64 26 3.2 (1.6-6.2) < 0.001
Female gender 48 20 2.9 (1.4-5.8) 0.002
NNHCA IE 30 15 3.9 (1.7-8.6) 0.001 6.0 (2.3-16.1) < 0.001
Nosocomial IE 22 9 2.3 (0.9-5.8) 0.068
Prosthetic valve 18 9 3.4 (1.3-9.2) 0.019
Staphylococci 115 35 2.0 (1.0-4.0) 0.039 3.0 (1.1-8.0) 0.027
Streptococci 57 6 0.3 (0.1-0.7) 0.003
Underlying conditions
Diabetes mellitus 52 24 4.0 (2.0-8.0) < 0.001
Hypertension 54 18 1.8 (0.9-3.5) 0.098
Predisposing heart condition 49 14 1.3 (0.6-2.6) 0.506
IVDU 59 10 0.5 (0.2-1.1) 0.089
Charlson comorbidity index ≧ 2 68 30 4.4 (2.3-8.7) < 0.001
Symptoms
Constitutional 142 34 0.8 (0.4-1.7) 0.589
Cardiopulmonary 65 18 1.2 (0.6-2.4) 0.542
Neurological 47 15 1.6 (0.8-3.2) 0.211
Gastrointestinal 14 4 1.2 (0.4-4.1) 0.749
Musculoskeletal 24 5 0.8 (0.3-2.2) 0.615
Signs
Fever 165 41 1.0 (0.4-2.2) 0.914
Heart murmur 83 19 0.8 (0.4-1.6) 0.562
Alteration in consciousness 34 15 3.0 (1.4-6.4) 0.005 3.9 (1.4-11.1) 0.012
Shock 20 13 7.2 (2.7-19.3) < 0.001 7.8 (2.4-25.2) 0.001
Unrecognition on admission
2 94/162 25 1.3 (0.6-2.7) 0.509
Delay of appropriate antibiotics
3 71/165 24 2.9 (1.4-6.2) 0.004 3.7 (1.5-9.1) 0.004
1 Adjusted for age and sex.
2 Patients who were not suspected or diagnosed to have IE within the first 24 hours of medical access.
3 Patients didn’t receive antibiotics with in vitro activities against the pathogens within the first 24 hours of medical access.
IE, infective endocarditis; OR, odds ratio; CI, confidence interval; NNHCA, non-nosocomial healthcare-associated; IVDU, intravenous drug user
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predictor for in-hospital death in all IE patients, but not
in NNHCA-IE patients. We propose two possible expla-
nations. First, patients with NNHCA-IE had more
underlying diseases, which were mainly responsible for
the poor outcome and masked the impact of inappropri-
ate antimicrobial therapy. Second, the case number of
NNHCA-IE in our series was small. Further larger, pro-
spective studies may be needed to evaluate the impact
of inappropriate antimicrobial therapy on NNHCA-IE.
NNHCA-IE is an emerging category of IE. In a popula-
tion-based study of IE, 50% of IE patients between 2001
and 2006 were non-nosocomial healthcare-associated.
The percentage was higher than that of community-
acquired IE (42.5%) and nosocomial IE (7.5%) [31]. In
our study, NNHCA-IE accounted for 15% of all IE epi-
sodes. This is similar to the rates in the ICE-PCS study
(254/1622, 15.7%) [14]. The rates of NNHCA-IE in
Taiwan were lower than those in North America, but
higher than South America and Europe [15]. Non-noso-
comial acquisition accounted for 58% of health care-asso-
ciated IE episodes at our medical center. This is slightly
higher than the 46% reported in ICE-PCS [14]. Taiwan is
a country in which 99.5% of the population is covered by
national health insurance. This has augmented access to
medical clinics, regional hospitals, hemodialysis and
chronic care centers. Improved access to medical care,
accompanied by advances in invasive medical procedures,
increased the proportion of outpatient procedures and
care, which further contributed to the frequency of
NNHCA-IE.
There are only limited reports of the microbiological
epidemiology of IE in Eastern Asian countries during the
past decade [4,5,19-21,23]. Some report Staphylococci
[19-21], others found Streptococci [4,5,23] to be most com-
mon pathogens. None of these studies included the under-
lying risk factors for the new classification of IE. We found
Staphylococcus aureus to be the most frequent causative
pathogen, except for non-IVDU community-acquired IE,
where viridans Streptococci remain the predominant
pathogen. Our findings are in accordance with those in
the ICE-PCS [14]. The major difference was that our study
population had a relatively low proportion of Enterococci
(4.5%) compared to 8.0%-19.5% in western countries
[1,2,7,8,11,15,32,33].
We identified 5 risk factors for in-hospital death by
multivariate logistic regression analysis. Most are known
independent predictors of mortality. These included
shock [2,5], non-nosocomial healthcare-associated infec-
tion, alteration in consciousness [4,5], delay of appropri-
a t ea n t i b i o t i c su s e[ 3 4 , 3 5 ]a n dStaphylococci infection
[5,14]. Healthcare-associated infection has been identified
to be associated with poor outcome in IE [14]. In our
study, patients with non-nosocomial acquisition had an
even higher risk for in-hospital death. Patients with
NNHCA-IE also had many comorbid conditions requir-
ing frequent medical care and exposure. Increased aware-
ness of clinicians to this disease entity could reduce
mortality associated with NNHCA-IE.
This current study has several limitations. First, the ret-
rospective design of the current study may have missed
some clinical features such as new heart murmurs or
ascertainment of healthcare-associated criteria in some of
the community-acquired IE cases. Second, we were
unable to determine long-term survival and emergence
of further complications following discharge from the
hospital. Third, it was conducted in a single teaching
hospital. Nevertheless, the age and sex of patients were
comparable to those in previous studies [4,5,19], includ-
ing the large Taiwan nationwide population-based IE
study that included 7240 patients [5].
Conclusions
In conclusion, NNHCA-IE accounted for 15% of IE in
Taiwan, but was frequently unrecognized. It was asso-
ciated with a higher in-hospital mortality rate than com-
munity-acquired IE. Increased awareness of this new
category of IE is crucial to optimize therapy and improve
the outcome associated with this entity.
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